COMPARATIVE ANALYSIS OF SYMPTOM RELAPSE RATE FOLLOWING TREATMENT WITH PROTON PUMP INHIBITORS AND H2 RECEPTOR BLOCKERS
| Main Author: | Afshan Siddiqui, Mahesh Kumar Lohano, Munir Ahmed Channa, Aatir H. Rajput, Muhammad Muneeb, Abid Ali, Anam Shaikh7 & Tahir Hanif |
|---|---|
| Format: | Article |
| Bahasa: | eng |
| Terbitan: |
, 2018
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/1490723 |
Daftar Isi:
- Background:H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are the primary classes of medication prescribed to treat gastroesophageal reflux disease (GERD) patients. Both classes of medication are safe and well tolerated, with a low risk of adverse events. However, they are often overused fearing symptom relapse following withdrawal of therapy.Objective:To study the symptom relapse rate following treatment withdrawal of PPIs and H2RAs and to compare the individual relapse rates.Methods:This cross-sectional, observational analysis was carried out at Indus Medical College Hospital, T.M.K from January 2018 to July 2018 on a sample of 377 patients aged 18 to 48 years (chosen via non-probability, consecutive sampling) presenting with GERD. After taking written informed consent from subjects, data was collected using a pre-structured, interview based questionnaire containing inquiries about basic sociodemographic details, lifestyle and eating habits and self-reported symptoms of GERD (epigastric pain and post-prandial distress). The patients were approached to inquire about self-reported symptoms post treatment withdrawal after every four weeks for 3 months. The data obtained was analyzed using MS. Excel 360 and SPSS v. 21.0. Result:A total of 377 subjects were enrolled during the study duration. The mean age of sample stood at 27 years (SD ±7.5) and most of the subjects (71.35%) were males. 53.58% of the subjects had been taking H2RAs or PPIs continuously for over 2 months while the remaining had been under said treatment for less than 2 months. Following treatment withdrawal, symptoms (meriting reinstating of therapy) relapsed on week 8 for PPIs and week 6 for H2RAs. The self-reported symptom score steadily rose after week 4 and peaked at week 12. Conclusion: After carefully considering the results, it can be concluded that the symptom relapse rate for PPIs is considerably longer than H2RAs. Additionally, the PPI group enjoyed a lower self-reported symptom score for the entire withdrawal period. Keywords: Proton Pump Inhibitor, H2 Receptor Antagonist, Gastro-Esophageal Reflux Disease, Symptom Relapse and Disease Recurrence.